Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O1098-O1105

  Ghosh, N ^a   Chavada, R ^a   Maley, M ^a   van Hal, S J ^b  

^a LIVERPOOL HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Broth microdilution; Creatinine clearance; Etest; Minimum inhibitory concentration; Pharmacodynamics

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BROTH DILUTION; COHORT ANALYSIS; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; OBSERVATIONAL STUDY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BACTEREMIA; BLOOD; DRUG EFFECTS; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTEREMIA; COHORT STUDIES; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN; YOUNG ADULT;

EID: 84920403059     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12695     Document Type: Article

References (31)

1. Price J, Baker G, Heath I et al. Clinical and microbiological determinants of outcome in Staphylococcus aureus bacteraemia. Int J Microbiol 2010; 2010: 654858.
2. Turnidge JD, Kotsanas D, Munckhof W et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009; 191: 368-373.
3. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012; 25: 362-386.
4. van Hal SJ, Fowler VG Jr. Reply to Parra-Ruiz. Clin Infect Dis 2013; 57: 1219-1220.
5. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
6. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-e55.
7. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-942.
8. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
9. Brown J, Brown K, Forrest A. Vancomycin auc24/mic ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 2012; 56: 634-638.
10. Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA. A stewardship program's retrospective evaluation of vancomycin auc24/mic and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 2013; 35: 772-779.
11. Holmes NE, Turnidge JD, Munckhof WJ et al. Vancomycin auc/mic ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013; 57: 1654-1663.
12. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-981.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-2144.
14. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 1536-1542.
15. Kullar R, Leonard SN, Davis SL et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/l suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011; 31: 441-448.
16. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-771.
17. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57: 734-744.
18. Avent ML, Vaska VL, Rogers BA et al. Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 2013; 43: 110-119.
19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE APACHE II: a severity of disease classification system. Crit Care 1985; 13: 818-829.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: M100-S16. Wayne, PA, USA: CLSI, 2006.
21. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848-852.
22. Cockcroft DW, Gault MH. Rediction of creatinine clearance from serum creatinine. Nephron 1976; 6: 1-41.
23. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
24. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-3320.
25. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-1266.
26. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-514.
27. Fowler VG Jr, Miro JM, Hoen B et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293: 3012-3021.
28. Neely MN, Youn G, Jones B et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014; 58: 309-316.
29. Rybak MJ, Vidaillac C, Sader HS et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol 2013; 51: 2077-2081.
30. van Hal SJ, Barbagiannakos T, Jones M et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66: 2284-2287.
31. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011; 55: 4277-4282.